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Collective cancer invasion forms an
integrin-dependent radioresistant niche
Anna Haeger1*, Stephanie Alexander2,3,4*, Manon Vullings1, Fabian M.P. Kaiser3, Cornelia Veelken1, Uta Flucke5, Gudrun E. Koehl6, Markus Hirschberg2,3,
Michael Flentje7, Robert M. Hoffman8,9, Edward K. Geissler6, Stephan Kissler3, and Peter Friedl1,2,3,4
Cancer fatalities result frommetastatic dissemination and therapy resistance, both processes that depend on signals from the
tumor microenvironment. To identify how invasion and resistance programs cooperate, we used intravital microscopy of
orthotopic sarcoma and melanoma xenografts. We demonstrate that these tumors invade collectively and that, specifically,
cells within the invasion zone acquire increased resistance to radiotherapy, rapidly normalize DNA damage, and preferentially
survive. Using a candidate-based approach to identify effectors of invasion-associated resistance, we targeted β1 and αVβ3/β5
integrins, essential extracellular matrix receptors in mesenchymal tumors, which mediate cancer progression and resistance.
Combining radiotherapy with β1 or αV integrin monotargeting in invading tumors led to relapse and metastasis in 40–60% of
the cohort, in line with recently failed clinical trials individually targeting integrins. However, when combined, anti-β1/αV
integrin dual targeting achieved relapse-free radiosensitization and prevented metastatic escape. Collectively, invading
cancer cells thus withstand radiotherapy and DNA damage by β1/αVβ3/β5 integrin cross-talk, but efficient radiosensitization
can be achieved by multiple integrin targeting.
Introduction
Metastatic progression of cancer is initiated by neoplastic cells
leaving the primary tumor to migrate into the tumor-free mi-
croenvironment (Nieto et al., 2016). Invading cancer cells re-
ceive tumor stroma–derived signals which enhance both their
metastatic and survival potential (Alexander and Friedl, 2012;
Hirata et al., 2015; Pickup et al., 2014), including hypoxia-related
and/or metabolic stress and adhesion signaling (Hirata et al.,
2015; Verduzco et al., 2015; Rahbari et al., 2016). Multiple en-
vironmental signals may cooperate to form complex activation
networks (Alexander and Friedl, 2012; Domoto et al., 2016);
however, genomically and functionally, those evolving tumor
subregions that depend on invasive abilities, and account for
differential survival and resistance, remain poorly defined.
Cancer invasion occurs through individual or collective cell
migration (Nieto et al., 2016; Friedl et al., 2012). Moving single
cells detach from the primary site and deliver high numbers of
circulating tumor cells with limited probability to survive the
metastatic cascade (Smerage et al., 2013; Cheung et al., 2016).
Alternatively, collective metastasis empowers grouped cells to
invade, circulate, and colonize distant organs with low fre-
quency but high efficacy through cell-to-cell cooperation (Aceto
et al., 2014; Cheung et al., 2016). While the particular ability of
collective processes for metastatic progression is becoming ap-
preciated, their significance for the therapy response remains
unclear (Cheung and Ewald, 2016).
For invasion, tumor cells engage a range of mechano-
transduction systems, including integrin-based adhesion sys-
tems, which mediate cell–matrix interactions and migration as
well as anti-apoptosis and therapy resistance programs (Guo and
Giancotti, 2004; Park et al., 2008; Eke et al., 2012; Naci et al.,
2012; Ahmed et al., 2013, 2018; Yamaguchi et al., 2015). For ex-
ample, β1 integrins interacting with fibronectin and other
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extracellular matrix (ECM) ligands mediate chemoresistance
and resistance to oncogenic BRAF or MAPK/ERK inhibitor
treatment (Kanda et al., 2013; Fedorenko et al., 2016; Naci et al.,
2012), and expression of αVβ3 integrin in breast, lung, or pan-
creatic carcinomas characterizes a fraction of cells with stem-
like properties that resist tyrosine kinase inhibitors (Seguin
et al., 2014). Similarly, disseminated nonproliferating breast
cancer cells resort to β1 integrin–dependent survival signaling
for long-term persistence (Carlson et al., 2019), suggesting that
anti-integrin therapy might reduce metastatic burden and re-
lapse. Integrins or their downstream signaling networks are
being explored for overcoming cancer resistance (Vehlow et al.,
2016; Raab-Westphal et al., 2017). Single-agent targeting of in-
tegrins, however, has failed to reach clinical endpoints in de-
laying advanced cancers, even in continuous or antibody-based
delivery schemes and in combination with cytotoxic therapies
(Vehlow et al., 2016; Élez et al., 2015). The resilience of estab-
lished lesions in both preclinical tumor models and clinical
cancers to withstand integrin-targeted therapy may result from
compensatory signaling through growth factors and other ECM
receptors (Raab-Westphal et al., 2017; Nieto et al., 2016), and
further may be supported by cross-talk from multiple integrin
subsets and alternative ECM interactions. Integrin expression
varies depending on tumor type and tissue context. They may
overlap in ligand-binding specificity and coordinate adaptive
signaling to promote DNA damage repair, cell survival, and tu-
mor progression (Ahmed et al., 2018; Winograd-Katz et al., 2014;
Eke and Cordes, 2015; Janes and Watt, 2004; Hodkinson et al.,
2006). Yet their cross-talk in solid tumors and the efficacy of
multi-integrin targeting remain unexplored.
To address which tumor regions are especially dependent on
integrins for survival and resistance development, we here
combined preclinical intravital microscopy with in situ and
long-term survival analysis during radiation therapy in ortho-
topic mouse models of sarcoma and melanoma. We identify
collective invasion as a niche for accelerated DNA damage re-
sponse (DDR) and integrin-dependent radiation resistance. We
find that combined β1/αV integrin targeting, but not interfer-
ence with either integrin subset alone, effectively radio-
sensitizes and ablates local disease and suppresses metastatic
progression.
Results
Collective invasion in orthotopic sarcoma and
melanoma xenografts
To identify tumor subregions of therapy resistance and test
whether invasion and survival programs coincide, wemonitored
fluorescent orthotopic HT-1080 sarcoma and MV3 melanoma
xenografts in the mouse dermis during invasion and response to
preclinical therapy using longitudinal intravital multiphoton
microscopy (Alexander et al., 2008). Originating from the
growing tumor, both sarcoma and melanoma lesions developed
deep invasion of the dermis (mean velocity ∼100 µm/d; Fig. S1,
A–C), with >98% of the cells moving collectively, as continuous
strands connected to the tumor core, or as detached clusters
(Fig. 1, A–C; and Videos 1 and 2). Intact cell–cell junctions and
collective polarity were verified from (i) linear enrichment of
the homophilic adhesion receptor ALCAM (CD166) between in-
vading HT-1080 and MV3 cells (Fig. 1 D), (ii) collective front-
rear polarity with mitotic planes aligned perpendicular to the
invasion direction (Fig. S1 D), and (iii) multicellular orientation
along tissue landmarks such as collagen bundles, myofibers, and
perfused blood vessels (Fig. 1, B and D; Weigelin et al., 2012).
These collective patterns obtained in the mouse model recapit-
ulated the predominantly multicellular strands and nest-like
patterns of tumor cells in the invasion zone of clinical sarcoma
and melanoma specimens (Fig. S1, E and F; Eyden et al., 1998;
Clark et al., 1969).
Collective invasion represents a radioresistive niche
We next addressed whether tumor subregions, including the
collective invasion niche, responded differentially to genotoxic
therapy. In disseminated clinical sarcoma, DNA-damaging ra-
diotherapy is highly effective; however, patient subsets
(10–20%) with advanced tumors develop resistance and/or ex-
perience local toxicity and compromised organ function due to
high radiation doses (Haas et al., 2015, 2018; Gorayski et al.,
2015; Espenel et al., 2017; Guadagnolo et al., 2014). Melanoma
requires particularly high cumulative radiation doses, which
limits the applicability of radiotherapy in functionally sensitive
regions (Mahadevan et al., 2015; Espenel et al., 2017). To reliably
eliminate locally advanced or resistant tumors, radioenhancing
strategies are being explored preclinically and clinically, among
them the use of MEK inhibitors and anti-angiogenic agents
(Haas et al., 2015).
As an irradiation (IR) scheme enabling homogeneous and
sustained exposure across all tumor regions, isometric whole-
field IR and fractionation were applied in invading tumors after
the angiogenic switch, as seen by the presence of perfused blood
vessels within the tumor core (Fig. 2 A and Fig. S2, A and B). IR
has the notable experimental advantage that it avoids pharma-
codynamic issues such as varying or inadequate compound de-
livery to tumor subregions due to heterogeneous vascular
perfusion or pressure distribution (Tolaney et al., 2015). IR, by
contrast, applies an identical level of genotoxic stress over large
tumor regions and so addresses possible heterogeneities in lo-
coregional response. Fractionated IR induced mitotic arrest
within hours in both the tumor core and the invasion zone,
followed by cell death (Fig. 2, B and C; and Fig. S2, C and E) and
substantial tumor regression a few days later (Fig. 2, D and E;
and Fig. S2, F and G). Cell death was identified by three-
dimensional (3D) intravital reconstruction and single-cell
analysis of nuclear fragmentation and/or disappearance of the
cytoplasmic label in vivo (Fig. 2, B and G). After IR in vitro,
nuclear fragmentation coincided with positive staining for
cleaved caspase-3 in organotypic invasion culture (Fig. S2 H).
Despite overall tumor regression, induction of cell death varied
significantly between different regions of the tumor. Whereas
background levels of nuclear fragmentation in untreated mice
were similar between the tumor core and the invasion zone,
nuclear fragmentation in the tumor core was elevated at least
fourfold but tended to only mildly increase, by twofold, in the
invasion zone (Fig. 2, B–D; and Fig. S2, D and E). As a
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consequence, with time, invading cells tended to survive or
marginally expanded, whereas the core regressed (Fig. 2 F).
Time-gated quantification of the surviving subsets in HT-1080
tumors showed that at 8 d after IR, when there was profound
regression of the tumor core, in the invasion zone >99% of the
cells survived in collective invasion strands and clusters, based
on cytoplasmic DsRed2 signal (Fig. 2 G, green label) and intact
nuclei (Video 3). Conversely, the frequency of solitary invasive
cells decreased from day 6 to 14 from 1.4 ± 1.1% to 0.7 ± 0.7%
(Fig. 2 G), indicating that the rare single cells disseminating
in vivo are at least twofold less likely to survive after IR com-
pared with grouped cells. These data strongly indicate that col-
lective invasion is a niche for relative radioresistance in an
otherwise radiosensitive tumor.
Accelerated DDR in the invasion niche
In brain tumors, tumor cell invasion was reported to associate
with decreased cell proliferation, which could account for in-
creased resistance toward DNA-damaging radiation therapy
(Giese et al., 1996; Roth et al., 2000; Hsu et al., 1962). However,
both HT-1080 and MV3 melanoma models show similar prolif-
eration in the invasion zones of untreated tumors and similarly
undergo mitosis arrest during fractionated IR (Fig. S2, C and E).
This suggests that cell cycle–dependent effects may not support
preferential survival of the invasion niche. Instead, cells in the
two subregions might deal differentially with the radiotherapy-
induced damage. IR causes DNA double-strand breaks (DSBs),
followed by a DDR with DNA repair or apoptosis induction as
outcomes (Ciccia and Elledge, 2010; Zannini et al., 2014). To
explore whether the tumor core and the invading niche differ in
their DDR, we performed quantitative subregion analysis of
central DDR effectors in untreated and irradiated lesions (Fig. 3,
A–C; and Fig. S3, A–E). Both HT-1080 and MV3 cells express
wild-type P53 (Tarunina and Jenkins, 1993; Houben et al., 2011)
and thus are competent to undergo cell cycle arrest and DNA
repair after DNA damage (Ciccia and Elledge, 2010). 30–60 min
after IR, the general DSB marker γH2AX (Rogakou et al., 1998)
was induced with equal (HT-1080) or mildly increased (MV3)
levels in the invasion zone relative to the core (Fig. 3, D and E;
and Fig. S3 F). This indicates uniform initiation of the DDR
across the tumor. The low γH2AX baseline in invading cells rules
out preset DSB elevation possibly induced by mechanical dam-
age of the nucleus during collective invasion (Denais et al., 2016)
or other microenvironmental assault, e.g., by reactive oxygen
species (Martinez-Outschoorn et al., 2010; Radisky et al., 2005).
CHK2 phosphorylation, which activates CHK2 and controls DDR
outcome (Zannini et al., 2014), was similar in all tumor regions
shortly after IR and reverted to baseline in the collective inva-
sion zone 1 d later but remained elevated in the tumor core
(Fig. 3, D and E; and Fig. S3, F and G). Similarly, phosphorylated
ATM/ATR substrates, which also include CHK2, P53, BRCA1 and
further effectors (Zannini et al., 2014; Shiloh and Ziv, 2013),
decreased in the invasion zone of HT-1080 lesions after 24 h but
remained elevated in the core (Fig. 3 E). CHK2 kinase has a dual
role in the DDR, including induction of cell cycle arrest, which
supports DSB repair, or induction of apoptosis in case damage is
Figure 1. Collective invasion as primary invasion pattern in sarcoma and melanoma xenografts. (A) Schematic view defining tumor core and collective
invasion zone (CI) of tumors growing in the deep dermis of the mouse monitored intravitally through an imaging window. (B) Collective invasion strands of
human HT-1080 sarcoma (left; day 7; see also Video 1) and MV3 melanoma xenografts (right; day 8; see also Video 2). Tumor cells stably express nuclear H2B-
EGFP and cytoplasmic DsRed2. Alexa Fluor 660–conjugated dextran contrastsperfused blood vessels. Second harmonic generation (SHG) visualizes muscle and
collagen fibers. Arrowheads, alignment of invasion strands with perfused blood vessels. Scale bar, 100 µm. (C) Prevalence of invasion types, including in-
dividual cells, detached clusters, or collective strands connected to the core (day 5–7). Data represent the means and SD from five (HT-1080) and three (MV3)
tumors. Per tumor, on average 150 (HT-1080) and 300 (MV3) cells were analyzed. (D) Distribution of ALCAM along cell–cell junctions (arrowheads) in invading
tumor strands. Maximum-intensity projections (overview) and individual sections (insets) from confocal 3D stacks. Diffuse background fluorescence originates
from fat (F) and myofibers (M). Scale bars, 100 µm (overview); 10 µm (insets).
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Figure 2. Collective invasion niche mediates
radioresistance. (A) Experimental procedure for
sequential intravital imaging of the tumor re-
sponse to fractionated IR. Fluo, epifluorescence
overviewmicroscopy. MPM, subcellular-resolved
multiphoton microscopy. (B) Differential re-
sponse to radiation therapy in invasion strands
and tumor core. Multiphoton microscopy images
show the borders between core and collective
invasion zone (day 13). Black box in lower right
corner (MV3) results from stitching of adjacent
images without complete overlap. Asterisk, re-
gressing tumor core. Circles and insets in lower
panel, nuclear fragmentation used for quantifi-
cation of dead cells. Scale bars, 50 µm. (C) Fre-
quency of fragmented nuclei indicating dead cells
in HT-1080 tumor cores and collective invasion
strands. Data represent medians, 25th/75th
percentiles (box), and 5th/95th percentiles
(whiskers) of ∼80 nuclei per tumor region from
5–20 fields/tumor from three to four indepen-
dent mice. *, P = 0.005; ***, P < 0.0001; ns, not
significant. Statistics, Mann–Whitney U test
(Bonferroni-corrected threshold: P = 0.008). (D)
Epifluorescence overviews of whole-tumor to-
pology in untreated and irradiated HT-1080 (5 ×
8 Gy) and MV3 (5 × 10 Gy) lesions (day 13). Im-
ages are derived from Fig. S1 A (control) and Fig.
S2 G (irradiated). Scale bar, 1 mm. (E) HT-1080
tumor growth before, during (dashed lines; 5 × 8
Gy), and after IR, compared with untreated tu-
mors in independent mice (Ext Ctrl) or nonirra-
diated contralateral tumors in the same mouse
(Int Ctrl). Means ± SD (three to nine independent
tumors). *, P = 0.02 (difference between irradi-
ated and control tumors at the endpoint [day
13]). Statistics, Mann–Whitney U test. (F) Extent
of tumor regression in core and invasion zone of
irradiated tumors. Data show median residual
areas, 25th/75th percentiles (box), and 5th/95th
percentiles (whiskers) of day 13 normalized to
day 6 from four independent tumors per condi-
tion. *, P = 0.03. Statistics, paired t test.
(G) Collective survival niche after IR. Multipho-
ton microscopy image shows the border be-
tween core and invasion zone of an irradiated
HT-1080 tumor (day 14). Persisting, invading
cells were quantified as individual or collective
cell patterns connected by the DsRed2-positive
cytosol. Dead cells were lacking cytoplasmic
signal. Asterisk, regressing tumor core. Scale
bars, 100 µm. (H) Classification of surviving, in-
vading cells based on the migration pattern, in-
cluding individual cells or collective strands. Data
represent the means and SD from three tumors
(HT-1080). ***, P < 0.0001. Statistics, paired
t test.
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Figure 3. Differential DDR in tumor core and collective invasion niche. (A) Experimental procedure for tumor sample collection to analyze the DDR. Fluo,
epifluorescence overview microscopy. (B) Strategy for differential immunohistological analysis of DDR in tumor core and collective invasion (CI) zone. Upper
panel, serial sectioning of the entire tumor; lower panels, resulting cross-sectioned patterns. (C) γH2AX and pChk2 signal in tumor core and collective invasion
zone detected at early (≤1 h) and late (24 h) time point after a single-dose IR. Maximum-intensity projections from confocal 3D stacks. Dashed rectangles
indicate representative tumor nuclei for single-channel display of γH2AX or pChk2 signal. H2B, H2B-EGFP (tumor nuclei). Images were chosen to show the
variation of the intensity and subcellular structure of positive events. Scale bars, 50 µm (overview); 25 µm (inset). Examples for nonirradiated samples are
shown in Fig. S3 E. (D) Intensity distribution of DDR signals in HT-1080 tumors after a single-dose IR. Data show the mean gray value after background
correction (lines) and signal range (filled areas, lowest to highest values) from three independent tumors. Dark gray shaded area, difference between core and
collective invasion zone. (E) Quantification of γH2AX, pATM/ATR substrates, and pChk2 signal intensity after single-dose IR. Data represent the median gray
value per nucleus after background correction, with 25th/75th (box) and 5th/95th percentiles (whiskers) from three independent tumors.∼150–600 nuclei per
invasion zone and tumor and ∼1,000–6,000 representative nuclei per core and tumor were analyzed. Dashed lines visualize approximate dynamics of DDR.
**, P = 0.003; ***, P < 0.0001. Statistics, mixed-model ANOVA (see Materials and methods for details).
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irreparable (Zannini et al., 2014). Thus, the observed prolonged
CHK2 phosphorylation (Fig. 3 E and Fig. S3 F) in associationwith
local regression of the core (Fig. 2, B and F) suggests that per-
sisting irreparable DNA damage is associated with cell death.
Conversely, timely normalization of Chk2 activity followed by
cell survival in the collective invasion niche indicates an effi-
cient repair of DNA damage (Fig. 2, B and F).
Combined β1 and β3 integrin functions underlie
invasion-associated radioresistance
When we probed for vascular integrity by assessing the reten-
tion of intravascular dextran (Fig. 1 B and Fig. 2 B), or for tissue
hypoxia using pimonidazole staining (Fig. S1 G), we found that
invading sarcoma and melanoma cells engaged with morpho-
logically intact, well-perfused, and metabolically unperturbed
dermal stroma. These results suggest that hypoxia-mediated
resistance is unlikely (Verduzco et al., 2015). We therefore
tested whether integrins, which are expressed and engaged
during collective invasion (Yamaguchi et al., 2015; Hegerfeldt
et al., 2002) and have been implicated in mediating radio-
resistance (Park et al., 2008; Monferran et al., 2008; Eke et al.,
2012; Mikkelsen et al., 2009), also orchestrate tumor cell sur-
vival during invasion in vivo. HT-1080 and MV3 cells expressed
high levels of β1 integrin and low to moderate levels of β3 and β5
integrin and lacked other β integrin subsets (Fig. S4, A and B).
We initially focused on the function of β1 and β3 integrins in
mediating survival during collective invasion, based on their
established role in mediating radioresistance in primary and
metastatic cancer models (Yamaguchi et al., 2015; Park et al.,
2008; Eke et al., 2012; Ahmed et al., 2013, 2018; Guo and
Giancotti, 2004). β1 Integrins alone or, to account for potential
compensation, together with β3 integrins, were downregulated
in HT-1080 cells by stable RNA interference (RNAi), yielding
∼80% reduction of extracellular β1 integrin expression (Fig. S4,
C–E). The remaining β1 integrin level was sufficient to maintain
cellular attachment, and no major growth deficit was noted
during propagation in cell culture (data not shown); this mini-
mizes the risk for a culture-based selection bias toward cell re-
programming to integrin and anchorage independence (Cerezo
et al., 2009). To maximize inhibition in vivo and target residual
β1 integrin chains, mice carrying HT-1080 shRNA-expressing
tumors additionally received human-selective anti-β1 integrin
antibody 4B4 (Fig. 4 A; Takada and Puzon, 1993). This regimen
repressed the β1 adhesion epitope by nearly 100% in vitro (Fig.
S4 F). In nonirradiated HT-1080 tumors, β1 and β1/β3 integrin
interference arrested mitosis, enhanced cell death, and retarded
growth in the tumor core (Fig. 4, B–D), similar to effects on
epithelial tumors and glioma (Park et al., 2008; Eke et al., 2012;
Ahmed et al., 2013, 2018; Carbonell et al., 2013). In situ MAPK
signaling, which supports cell growth and survival downstream
of integrins (Eke and Cordes, 2015), was diminished after β1/β3
integrin targeting to levels slightly below the stromal back-
ground (Fig. S4 G). Notably after integrin targeting, the tumor
core regressed, whereas the collective invasion zone retained
low-level mitotic activity and persisted beyond day 13; however,
with increased detachment of cell groups and individual cells as
also previously shown in vitro (Hegerfeldt et al., 2002; Fig. 4, B,
E, and F). The early-onset induction of cell death by mono-
versus dual-integrin targeting was comparable (Fig. 4 C); how-
ever, at later time points, marginally significantly enhanced
regression of both the tumor core and invasion zone was ach-
ieved by dual targeting (Fig. 4 D).
This indicates that the collective invasion niche withstands
anoikis induction after integrin deprivation by, e.g., acquiring
an anchorage-independent survival advantage (Paoli et al., 2013;
Gibert and Mehlen, 2015). This survival advantage, however,
was abrogated when β1 integrin targeting was combined with
fractionated IR, disrupting and shrinking the invasion zone
(Fig. 5, A and B). This effect was further 20-fold enhanced when
β1 and β3 integrins were simultaneously inhibited, reaching
effective regression of both the tumor core and collective inva-
sion niche within 3–5 d (Fig. 5, B–D). Since dual β1/β3 integrin
targeting was superior to β1 integrin monotargeting in radio-
sensitizing HT-1080 tumors, both integrins likely cooperate to
enhance cancer cell survival in invading cells.
Antibody-based dual β1 and αV integrin targeting to overcome
radioresistance
To verify these findings using a translational approach, and to
effectively target all expressed integrin subsets, including β1,
αVβ3, and αVβ5, multiple-integrin targeting was applied to HT-
1080 and MV3 tumors by systemic antibody application before
and during radiotherapy (Fig. 6 A). To interfere with αV inte-
grins on tumor cells and simultaneously target αVβ3 and αVβ5
integrins while avoiding interference with αIIbβ3 integrin ex-
pressed by platelets, which can induce bleeding as a side effect
(Hodivala-Dilke et al., 1999), we used human-selective anti-αV
integrin antibody 17E6, which selectively interferes with all αV
integrins (Fig. S4, A and B; Mitjans et al., 1995). When combined
with IR, antibody-based β1/αV integrin targeting induced rapid
and severe cell death followed by regression of the entire lesion
in both tumor types (Fig. 6, B and C; and Fig. S5, A–C). By day 7
after IR, HT-1080 tumor remnants consisted of few individual-
ized nondividing and slowly regressing cells in perivascular
position, of which very few cells persisted until day 28, when
animal welfare required termination of intravital monitoring
(Fig. 6, B and D; and Fig. S5, A, D, and E). Likewise, both tumor
core and invasion strands of MV3 lesions effectively regressed
with mitotically inactive scattered cells as remnants (Fig. 6, B
and D; and Fig. S5, D and E). The notable difference in regression
kinetics between the two tumor models replicates the higher
radiation sensitivity of clinical sarcoma compared with mela-
noma (Gorayski et al., 2015; Hoefkens et al., 2016). These data
indicate that combining antibody-based β1 and αVβ3/β5 integrin
targeting overcomes invasion-associated radioresistance and
ablates the collective invasion niche.
To address the radiosensitizing impact of single- versus
multiple-integrin targeting for long-term survival, fluorescent
HT-1080 and MV3 tumors were implanted into the imaging
window–free dermis under ultrasound control and followed for
180 d (Fig. 7, A and B; and Fig. S5 F). Mice bearing emerging
macroscopic and exponentially growing tumors were treated
with antibodies 4B4 and 17E6, individually or combined, and
irradiated using an adjusted, dose-conservative scheme
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Figure 4. Compromised tumor integrity and persistence of the invasion niche by RNAi- and antibody-based targeting of β1/β3 integrins in HT-1080
tumors. (A) Experimental procedure for administration of anti-β1 integrin mAb 4B4 or IgG1 and sequential intravital microscopy of the tumor response to
integrin interference. Fluo, epifluorescence overview microscopy. MPM, subcellular-resolved multiphoton microscopy. (B) Time course of tumor growth or
regression in control tumors transduced with empty vectors (p-puro/p-neo), β1RNAi or β1/β3RNAi in the absence or presence of IgG1 or anti-β1 integrin mAb
4B4. White arrowheads, onset of collective invasion. Numbers (right column), percentage mean regression of the tumor core (day 13 compared with day 6)
from three to four independent tumors. Scale bars, 1 mm. (C) Fractions of mitotic and dead cells (day 6) quantified based on nuclear morphology for different
interference schemes displayed as medians, 25th/75th percentiles (box), and 5th/95th percentiles (whiskers) from 20 independent fields from three to four
independent tumors. Per condition, 19–20 nuclei were analyzed for the core and ∼10 nuclei for the invasion zone. *, P = 0.01; ***, P < 0.0001; ns, not
significant. Statistics, Mann–Whitney U test (Bonferroni-corrected threshold: P = 0.0125). (D) Tumor development in response to the indicated interference
procedures. Data show the means ± SD from three to four independent tumors. *, P = 0.0286. Statistics, Mann–Whitney U test. (E) Preferential survival of
invading collective strands after combined β1/β3 integrin targeting. Z-projections of the same tumor region. Black box in upper left corner (day 6) results from
stitching of adjacent images without complete overlap. Insets, mitotic figures in collective strands. Arrowheads, detachment of cell groups and individualized
cells. Scale bar, 250 µm. (F) Median residual volume of tumor core and collective invasion (CI) zones after β1/β3RNAi combined with mAb 4B4 (day 13
compared with day 6) from three independent tumors. *, P < 0.05. Statistics, paired t test.
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(cumulative 10–15 Gy) to achieve relapsing disease in 70–80% of
the cohort receiving nontargeting IgG1 isotypic control antibody
(Fig. 7, A and D; and Fig. S5 G). To account for minimal residual
and metastatic disease, both tumor implantation site and distant
organs were dissected at the endpoint post mortem and assessed
for the presence of (disseminated) tumor cells (Fig. S5, H–J).
Tumors in window-free mice developed collective invasion as a
primary pattern (Fig. 7 C), ruling out artifacts caused by the
imaging window.
In contrast to the RNAi-based and early-onset antibody
treatment in small tumors, which was used to target integrins
for intravital multiphoton microscopy (compare Figs. 4 and 6),
antibody-based targeting of β1 and αV integrins without IR in
exponentially growing, established tumors did not provide a
relevant survival advantage. Upon radiotherapy, multiple-
integrin targeting significantly improved the radiation response,
resulting in local relapse-free outcome and overall survival in
80% (HT-1080) and >90% (MV3) of the mice (Fig. 7 D and Tables
S1 and S2). Individual targeting of either β1 or αV integrins failed
to substantially increase overall survival after IR (Fig. 7 D), similar
to relapsing disease after integrin monotargeting in epithelial and
glioma cancer models (Carbonell et al., 2013; Ahmed et al., 2013).
In addition, 90% (HT-1080) and 100% (MV3) of the mice re-
ceiving IR plus multiple-integrin targeting were free of distant
metastases (Tables S1 and S2). This lack of distant metastasis in
most mice suggests that cells were lethally damaged and failed to
exit the primary site. Alternatively, surviving cells, after leaving
the site of therapy, may have reached the lungs and reside with
long-term cell cycle arrest but fail to mount metastatic outgrowth
(Gérard and Goldbeter, 2014).
Discussion
These data identify mesenchymal collective invasion as a niche
for acquired radioresistance in vivo. We used human sarcoma
and melanoma models targeted by stable RNAi or human-
selective anti-integrin antibodies (Mahalingam et al., 2014;
Takada and Puzon, 1993; Mitjans et al., 1995), thereby ignoring
Figure 5. Radiosensitization of HT-1080 tumors by β1/β3 integrin RNA interference combined with antibody-based β1 integrin targeting. (A)
Protocol for administration of anti-β1 (4B4) or IgG1 combined with fractionated IR and sequential intravital imaging of the tumor response. Fluo, epifluor-
escence overviewmicroscopy. MPM, subcellular-resolved multiphoton microscopy. (B) Topology and extent of the invasion zone in response to fractionated IR
combined with single-integrin (β1) or dual β1/β3 integrin interference. Epifluorescence (left) and 3D reconstructed z-projections from regions marked by
dashed boxes using multiphoton microscopy (right; day 13). White asterisks, apoptotic nuclei. Scale bars, 1 mm (left); 250 µm (right). (C) Time-dependent
tumor volume. Data show the means ± SD from three to four independent tumors, with P values for comparing irradiated integrin-targeted tumors to ir-
radiated control tumors. (*), P = 0.006; *, P = 0.004. Statistics, Mann–Whitney U test (Bonferroni-corrected threshold: P = 0.005). (D) Regression of tumor
core and collective invasion (CI) zone after IR with or without integrin mono- or dual interference. Data show median residual areas, 25th/75th percentiles
(box), and 5th/95th percentiles (whiskers) of day 13 normalized to day 6. Per condition, four tumors were analyzed. (*), P = 0.03; ns, not significant. Statistics,
Mann–Whitney U test (Bonferroni-corrected threshold: P = 0.0125).
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any direct role of integrins present in the murine tumor mi-
croenvironment. These data reveal integrin-mediated resistance
as a tumor-cell intrinsic process arising with connective tissue
invasion (Mahalingam et al., 2014; Takada and Puzon, 1993;
Alexander and Friedl, 2012), which differs from stromal re-
programming by integrin adhesome–dependent signaling dur-
ing molecular targeted therapy (Hirata et al., 2015) or tumor
growth reduction after interference with vascular integrins
(Tolaney et al., 2015). β1 and αV integrin engagement in the deep
dermis is likely mediated by their connective tissue ligands,
collagens, laminins, fibronectins, vitronectin, and Cyr61 (Gibert
andMehlen, 2015; Weigelin et al., 2012; Mauger et al., 1987; Chen
et al., 2000; Dahlbäck et al., 1993). In contrast to hypoxia-
mediated metabolically induced cancer resistance (Verduzco
et al., 2015), the invasion niche is normoxic, therefore we con-
sidered hypoxia-mediated resistance programs as unlikely.
Functional blockade of β1 integrins in explant culture has been
shown to induce disruption of collective invasion and transition
to single-cell dissemination (Hegerfeldt et al., 2002), and a trend
to increased fragmentation of the collective invasion zone after
Figure 6. Dual-integrin targeting abrogates
radioresistance in the collective invasion ni-
che. (A) Protocol for administration of anti-
β1 (4B4) and αV integrin (17E6) mAbs or IgG1
combined with fractionated IR and sequential
intravital imaging of the tumor response. Fluo,
epifluorescence overview microscopy. MPM,
subcellular-resolved multiphoton microscopy.
(B) Radiation response of tumor core and col-
lective invasion zone after combined treatment
with mAbs 4B4 and 17E6 compared with IgG1-
treated control (day 13). Black box in upper right
corner (HT-1080, IgG1) results from stitching of
adjacent images without complete overlap. As-
terisks, areas of regression. Arrows, persisting
invasion strands. Alexa Fluor 660–conjugated
dextran-perfused blood vessels. Second har-
monic generation (SHG) originates from muscle
and collagen fibers. Scale bar, 250 µm. (C) Fre-
quency of dead cells in core and collective in-
vasion (CI) zone after antibody-based integrin
targeting and/or IR (day 6). Data show the me-
dians, 25th/75th percentiles (box), and 5th/95th
percentiles (whiskers) of ∼20 nuclei per condi-
tion and tumor regions from four to five tumors,
reflecting a total of 9–28 different microscopic
fields. *, P = 0.01; **, P = 0.001; ***, P < 0.0001;
ns, not significant. Statistics, Mann–Whitney U
test (Bonferroni-corrected threshold: P =
0.0125). (D) Extent of tumor regression in core
and collective invasion zone of irradiated tumors
combined with or without integrin targeting.
Data show median residual areas, 25th/75th
percentiles (box), and 5th/95th percentiles
(whiskers) of day 13 normalized to day 6 from
four independent tumors. *, P = 0.03. Statistics,
Mann–Whitney U test.
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combined β1 and αV integrin targeting was notable in vivo;
however, the majority of cells retained their collective invasion
pattern after integrin inhibition and IR, and additional strand
fragmentation may have occurred due to cell death. Therefore,
integrin targeting lowered the survival ability of the collective
invasion niche.
Integrin-mediated growth and survival signaling in response
to interaction with ECM has been identified in a range of epi-
thelial andmesenchymal tumors (Babel et al., 2017; Ahmed et al.,
2018; Leith et al., 2018). The integrin adhesome comprises a
complex, multisignal downstream network. This involves the
activation of focal adhesion kinase (FAK), Src, integrin-linked
kinase, and PINCH1, that then trigger and synergize with MAPK
and phosphoinositide 3-kinase signaling and downstream ef-
fectors, including MYC and NF-κB (Eke et al., 2012; Monferran
et al., 2008; Seguin et al., 2015; Winograd-Katz et al., 2014; Eke
and Cordes, 2015; Hodkinson et al., 2006; Janes andWatt, 2004).
Additional noncanonical effectors of integrin signaling further
include cross-talk with the CD44/hyaluronic acid axis, epider-
mal growth factor (EGF) receptor, and syndecan signaling (Yu
et al., 2000; Ghatak et al., 2014; McQuade et al., 2006). In head
and neck squamous cell carcinoma cells, β1 integrin activating
FAK/JNK1 is essential for the repair of radiation-induced DSBs,
and β1 integrin signaling supports expression of essential DNA
repair genes, including Ku70/80 and Rad51 (Dickreuter et al.,
2016; Ahmed et al., 2018). These data link integrin signaling to
Figure 7. Dual-targeted but not individual anti-integrin therapy to enhance radiation response, tumor eradication, and long-term survival. (A)
Treatment schemes for HT-1080 and MV3 tumors. Tumor cells were injected at day 0, resulting in an intradermally growing tumor located along the dorsal
midline (dashed line). Example image, intradermal HT-1080 lesion. Time points of IR and antibody administration are indicated. (B) Tumor lesion (T) after
implantation in imaging window–free mouse. Intradermal localization was confirmed by high-frequency ultrasound. (C) Collective invasion (CI) pattern in
intradermal tumors in imaging window–free dermis (maximum-intensity projections). Number of multicellular strands per tumor was counted from 50-µm-
thick tumor sections from nine (HT-1080) and seven (MV3) tumors. Scale bar, 100 µm. (D) Tumor-free overall survival of mice after application of treatment,
including fractionated IR without and with individual and dual-targeted integrin inhibition with antibodies 4B4 and/or 17E6, compared with IR combined with
isotypic control antibody (representing IR alone without integrin targeting). Mice were sacrificed after 180 d or earlier, upon humane endpoint criteria (tumor
size of 2 cm3, ulceration, weight loss, or poor overall condition due to internal metastasis). See Table S1 for details on mouse numbers (8–12 mice per group),
metastasis formation, and tumor remnants. Gray-shaded area, therapy phase. *, P = 0.01; **, P = 0.0003; ***, P < 0.0001; ns, not significant. Statistics, log-rank
survival analysis (Bonferroni-corrected thresholds: P = 0.01 [HT-1080] and P = 0.008 [MV3]).
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the major DSB repair pathways, nonhomologous end joining and
homologous recombination. However, the exact repair mecha-
nisms and precise signaling pathways that, downstream of in-
tegrins, support accelerated DNA damage repair and may
therefore account for resistance of the invasion niche in me-
senchymal sarcoma and melanoma tumors remain to be iden-
tified by future research.
By directly targeting integrin receptors upstream of the sig-
naling network, even moderate IR (cumulative doses of 10 to 15
Gy) entirely eliminated the tumor and prevented systemic mi-
cro- or macrometastasis. This indicates that targeting β1/αV
integrin upstream can reach particular efficacy in non-
redundantly perturbing the integrin adhesome and downstream
signaling, whereas interference with signaling intermediates
downstream of integrins (e.g., FAK, Src, MAPK) may trigger
network rewiring and development of resistance (Wellbrock
and Arozarena, 2016; Hirata et al., 2015; Vehlow et al., 2016).
Most known integrins and their downstream signaling have
been, individually and largely unsuccessfully, pursued for
therapeutic intervention (Raab-Westphal et al., 2017). Preclini-
cal efficacy of inhibiting individual integrins is commonly in-
complete in strength and/or duration (Kim et al., 2016; Élez
et al., 2015; Raab-Westphal et al., 2017; Vehlow et al., 2016),
and cells expressing multiple integrins may generate compen-
satory signaling by switching their integrin dependence (Janes
and Watt, 2004). In mesenchymal sarcoma and melanoma tu-
mors, β1/αV dual targeting, but not interference with either
subset alone, was sufficient to revert radioresistance in the in-
vasion niche. This combination potentially targets 15 of 16 in-
tegrin members expressed by mesenchymal and epithelial
tumor cells and previously tested in clinical trials, including α1-
11β1, αVβ3, αVβ5, αVβ6, and αVβ8 (Raab-Westphal et al., 2017).
In carcinomas, α6β4 and α6β7 integrins may mediate additional
cross-talk (Lu et al., 2008) and require cotargeting to minimize
resistance.
Importantly, for application in patients, future work needs to
secure the tolerability and applicability of combined β1/αV in-
tegrin targeting. Pan-αV integrin antagonists are clinically well
tolerated (Vehlow et al., 2016). Although not shown to be toxic in
mice (Park et al., 2006), targeting of β1 integrin, due to its
ubiquitous expression and pleiotropic functions, may require
particular caution, including time-restricted or intermittent
dosing and possibly preventive care to minimize leukocyte
malfunction or wound healing defects (Koivisto et al., 2014).
Clinical indications for combining multiple-integrin targeting
with radiotherapy particularly include perisurgery therapy of
advanced or deeply infiltrative tumors, to reduce local relapse
and surgery-induced systemic dissemination (Burmeister et al.,
2012; Jatana et al., 2016). Other indications may include relaps-
ing disease after radiation therapy and lowering radiation dose
to prevent loss of functionality of tissues susceptible to radiation
injury (e.g., head and neck region, axilla; Kris et al., 2017). Be-
sides radiosensitization, multiple-integrin inhibition may also
reduce resistance to chemotherapies and molecular targeted
therapies (Naci et al., 2015; Hirata et al., 2015). Combining
antibody-based integrin targeting with IR or chemotherapy may
boost both tumor-cell death and, via opsonization, tumor-
antigen uptake by phagocytes and augment checkpoint targeted
immunotherapy (Formenti and Demaria, 2013). In conclusion,
multi-integrin–targeted therapy provides rational opportunities
to improve DNA damaging therapy and eradicate niches of tumor
resistance in clinical settings.
Materials and methods
Cells and cell culture
Human HT-1080 sarcoma (Rasheed et al., 1974) and MV3 mel-
anoma cells (van Muijen et al., 1991) were cultured in DMEM
(PAN Biotech or Invitrogen) supplemented with 10% FCS (Au-
rion or Sigma-Aldrich), penicillin, and streptomycin (both
100 µg/ml; PAN Biotech or PAA Laboratories) at 37°C in a hu-
midified 5% CO2 atmosphere. Identity of the cells was verified by
SNP_ID Assay (Sequenom, MassArray System, Characterized
Cell Line Core Facility, MD Anderson Cancer Center, Houston,
TX), and lack of contamination with mycoplasma was routinely
verified using theMycoAlert Mycoplasma Detection Kit (Lonza).
Dual-color variants of HT-1080 and MV3 cells, expressing cy-
toplasmic DsRed2 and nuclear histone 2B (H2B)-EGFP
(Yamamoto et al., 2004), were cultured in medium additionally
containing hygromycin B (0.2 mg/ml; Invitrogen) and G418
sulfate (0.2 mg/ml; Calbiochem).
Generation of stable knockdown cell lines by lentiviral shRNA
ShRNA sequences targeting ITGB1 (β1 integrin, 59-AGCCACAGA
CATTTACATTAAA-39) and ITGB3 (β3 integrin, 59-AAGTCACTT
TCTTCTTCTTAAA-39) for gene silencing by RNAi were cloned
into the lentiviral vector pLBM containing either a puromycin
(p-puro) or a neomycin (p-neo) cassette, and lentiviral particles
were produced and concentrated by ultracentrifugation, as de-
scribed (Kissler et al., 2006). HT-1080 dual-color cells were in-
fected with p-puro or p-neo viruses (vector controls), or with
ITGB1 (on p-puro) or ITGB3 targeting (on p-neo) pLBM viruses.
For generation of double knockdown cells, HT-1080 p-puro or
HT-1080 β1RNAi cells were additionally infected with ITGB3
targeting or p-neo viruses, respectively. Efficiency of protein
downregulation wasmeasured byWestern blot (β1 integrin) and
flow cytometry (β1 and β3 integrin), showing ∼80% reduction
for β1 integrin and∼90% downregulation for β3 integrin (Fig. S4,
C–E). For maintaining stable HT-1080 knockdown cells, medium
was supplemented with puromycin (5 µg/ml; Sigma-Aldrich) for
single transfectants (single-vector control, β1RNAi) or puromy-
cin and G418 sulfate (400 µg/ml) for dual transfectants (dual-
vector control, β1/β3RNAi). Stability of knockdown without
antibiotics selection was confirmed after 4-wk culture in
antibiotic-free medium and before implantation into mice.
Animal experiments
All animal procedures were approved by the German regional
government (Regierung von Unterfranken; TVA_AZ 54-2531.01-
47_06) and the Ethical Committee on Animal Experiments of the
Radboud University, Nijmegen (RU-DEC 2011-124, 2011-230,
2013-008, 2013-125), in accordance with both the German and
Dutch Animal Experimentation Acts and the Federation of Eu-
ropean Laboratory Animal Science Associations protocol (http://
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www.felasa.eu/guidelines.php) or performed according to the
institutional guidelines for animal care and handling of the In-
stitutional Animal Care and Use Committee of The University of
Texas MD Anderson Cancer Center (ACUF 07-11-07631 and
-07632).
Skin window model, intravital microscopy, and image analysis
Dorsal skin imaging windows were transplanted onto 10–14-wk-
old male athymic Balb/c nude mice (CANN.CG-FOXN1NU/CRL;
Charles River), as described (Alexander et al., 2008). 1 d after
surgery, tumor cells (∼5 × 105 cells in 4 µl PBS) were implanted
into the dermis by image-guided microinjection. Tumor pro-
gression and therapy response were typically monitored for
≤14 d using a titanium window. In selected experiments, mon-
itoring for 26 d was achieved using a polyethylene window.
Tumors used for histological analysis of the DDR were harvested
4 or 5 d after implantation, representing the time point of ra-
diation therapy initiation. Dual-vector control xenografts
showed no significant differences in growth and invasion pa-
rameters compared with wild-type tumors and thus were used
interchangeably as controls. For intravital microscopy, live mice
were anesthetized with isofluorane and stably mounted onto a
temperature-controlled platform (37°C). Progression of dual-
color tumors was monitored using longitudinal multiphoton
microscopy (LaVision BioTech; Andresen et al., 2009; Weigelin
et al., 2015). By taking overview images of the entire tumor and
surrounding vascular network before subcellular multiphoton
microscopy, regions of interest for detailed image acquisition
could be repetitively annotated and traced over multiple days
and measurements. The emission ranges (in nm) were 400/40
(blue), 535/50 (green), 605/70 (red), and 710/75 (far-red). Epi-
fluorescence overviews of xenografts were obtained with a 4×
objective (numerical aperture [NA] 0.3) and subcellular-
resolved multiphoton microscopy with a 20× objective (NA
0.95; both Olympus). Sequential 3D stacks were obtained for
≤300-µm penetration depth at 5-µm step intervals. Perfused
blood vessels were visualized by i.v. injection of Alexa Fluor
660–conjugated dextran (70 kD, 1 mg/mouse; Invitrogen).
Images obtained during intravital microscopy were 3D re-
constructed, stitched, and analyzed using ImageJ v1.40g (Na-
tional Institutes of Health), ImSpector 3.4 (LaVision BioTec),
Photoshop CS 8.0.1 (Adobe Systems), and Volocity 4.0.1 (Im-
provision). Unless indicated otherwise, multiphoton micro-
graphs represent z-projections of 120–250-µm imaging depth.
Migration velocities were obtained by computer-assisted cell
tracking of invasion strand tips (Autocell software, Universities
of Bremen and Würzburg). Tumor volume from epifluorescence
overview images was calculated as [((tumor width)2 × (tumor
length) × π) / 6] /2, to account for partial flattening of the tumor
caused by the geometric constraints caused by the imaging
window (compare Fig. S1 G, core). Fractions of mitotic and dead
cells were determined from the morphology of tumor cell nuclei
identified by H2B-EGFP from 5–30 multiple visual fields (de-
pendent on analyzable cell amounts) from three to five inde-
pendent tumors. The orientation of mitotic planes was
expressed as angle relative to the length axis of the invasion
strand, measured in invading cells and the adjacent core of the
lesion. The classification of invasion mode of surviving cells
after IR was done based on the cytoplasmic DsRed2 marker: cells
were counted as collective when cytosols appeared connected.
This resulted in a sensitivity of 67% to detect collectively in-
vading cells and 100% detection rate for individual cells. The
extent of the residual tumor mass after treatments was mea-
sured as the area covered by the tumor core or invading cells at
day 13 normalized to the matching area of the same lesion at day
6 using stitched high-resolution overviews from 3D projections
obtained by multiphoton microscopy.
Long-term monitoring of intradermal tumors
Intradermal xenograft lesions without imaging window were
injected along the dorsal midline (∼104 cells in 20 µl PBS, 30G
needle, two tumors per mouse) sparing rostral and caudal zones.
Correct intradermal positioning of growing tumors was verified
by high-frequency ultrasound (DermaScan, Cortex Technology).
Tumor development and therapy response were monitored by
whole-body fluorescence imaging (FluorVivo100, INDEC Bio-
Systems) and caliper measurements of macroscopic nodules
(tumor volume = [(tumor width)2 × (tumor length) × π]/6).
Treatment of tumors was initiated at day 6 (HT-1080) or day 13
(MV3; Fig. 7 A), to secure a macroscopically visible tumor stage
and equal size distribution between different groups. Inclusion
criteria for treatment were at least one macroscopic,
fluorescence-positive, and exponentially growing tumor lesion
per mouse not exceeding a volume of 35 mm3 (HT-1080) or
40 mm3 (MV3). Before and during therapy, tumor development
was monitored every second day. After therapy was completed,
monitoring frequency was adjusted to the progression rate
ranging from three times a week (growing tumor) to two times a
month (complete regression) for up to 180 d. Humane endpoint
criteria were a tumor size of 2 cm3, ulceration, weight loss, or
poor overall condition due to internal metastasis. Sacrificed
animals were screened for the presence of tumor remnants in
the dorsal dermis, lymph nodes (superficial cervical, brachial,
inguinal), lung, liver, and brain using fluorescence stereo-
microscopy (Leica MZFLIII, NA 0.125, EL6000 external light
source, GFP Plus and DsRed filter sets). This fluorescence-based
approach to score organs for metastasis reliably detected micro-
and macrometastasis events, but not individual cells. Tumor
material and organs were embedded in optimal cutting tem-
perature compound (O.C.T.; Sakura), deeply frozen using dry ice
or through swaying in liquid nitrogen, stored at −80°C, and
analyzed for the presence or absence of tumor cells or invasion
status from 10–50-µm-thick cryosections (M500 or HM500OM
Cryostat Microtome; Microm) by epifluorescence microscopy
(Leica DMRA fluorescence microscope, Leica DFC340 FX charge-
coupled device camera, Cytofluor software; 2.5× to 40×
objectives, NA 0.07, 0.15, 0.3, 0.5, 0.75). A fixed monolayer of
HT-1080 or MV3 dual-color cells from in vitro culture served as
positive control to discriminate specific fluorescence from
autofluorescence.
Antibody treatment
Adhesion-perturbing mouse anti-human β1 (clone 4B4, IgG1,
1 mg/ml; 6603113; Beckman Coulter) and αV integrin (clone 17E6,
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batch 7299DA01.G01 and CH009, IgG1, 1 mg/ml, endotoxin level
0.4 EU/ml antibody; Merck Serono; kindly provided by Simon
Goodman, Department of Cellular Pharmacology Oncology
Platform, Merck, Darmstadt, Germany) mAb or mouse IgG1κ
isotype (clone MOPC-21, M7894, 1 mg/ml; Sigma-Aldrich) were
injected i.p. at 5 or 10 mg/kg body weight, respectively, to reach
a calculated antibody concentration of ∼8 µg/ml in body fluids
(60% of body weight; Chapman et al., 2010) which ranges more
than two times above the minimum concentration required for
99% integrin epitope saturation in vitro (Fig. S4 F and data not
shown). Based on an IgG1 half-life of 6–8 d (Vieira and Rajewsky,
1988), a calculated antibody concentration of >3 µg/ml in body
fluids is achieved for ≥6 d by a single injection, sufficient to
achieve >99% epitope saturation on HT1080 cells (Fig. S4 F). To
additionally secure sufficient availability during the therapy
phase, antibody was administered every 2–3 d starting with a
boost (two injections on two subsequent days). Both mAbs 4B4
and 17E6 recognize human-specific epitopes and do not cross-
react with murine integrins (Mahalingam et al., 2014; Takada
and Puzon, 1993), allowing selective targeting of integrins ex-
pressed by tumor compartment but not the murine stroma. For
application in vivo, NaN3-containing antibody stocks (mAb 4B4,
IgG1) were dialyzed against 0.9% NaCl using a dialysis tube with
14-kD exclusion limit (Roth). In mice carrying the imaging
window, antibody was administered at days 3, 4, 7, 10, and 13 as
a therapeutic intervention in established tumors after the onset
of invasion (Fig. 6 A). Mice carrying established tumors without
an imaging window received antibody on days 6 (before IR), 7, 9,
11, and 13 (HT-1080) or days 13 (before IR), 14, 16, 18, and 20
(MV3) after tumor implantation (Fig. 7 A).
IR procedures
Tumors in mice carrying the imaging window were irradiated
either locally with a focused beam of 2-cm diameter using a RT
50 (x-ray) source (Philips Medical Systems) at a dose rate of
4.9 Gy/min or with a wide-field beam using an x-ray tube
(X-RAD 320ix, Precision X-Ray) with 0.75-mm tin, 0.25-mm
copper, and 1.5-mm aluminum filter for beam conditioning, 30-
cm source-skin distance, 320-KV output voltage with 12.5 mA,
for a dose rate of 3.6 Gy/min. To shield the mouse body but
expose the tumor and peritumor tissue to the wide-field radia-
tion beam, the mouse was placed inside a 6-mm lead-coated
tube, while the tumor in the skin-fold window was exposed
through a slit. To irradiate tumors in imaging window–free mice
using the nonfocused beam, the mouse was positioned inside the
shielding tube and the skin fold containing the tumor was gently
extended through the slit, fixed by surgical tape and exposed to
the radiation field. By varying the duration of exposure, radia-
tion doses ranging from 2 to 10 Gy per session were applied. For
tumors growing in the imaging window, a fractionation scheme
with cumulative doses of 40 Gy for HT-1080 tumors (daily
fractionation from days 4 to 8) or 50 Gy for MV3 tumors (days 4,
5, 7, 8, and 11) was used (Fig. 2 A), to reach detectable response
curves within a 2-wk period for intravital microscopy. Tumors
used for the analysis of DNA damage markers received a single
dose of either 8 Gy (HT-1080) or 10 Gy (MV3) on day 4. Intra-
dermal tumors in imaging window–free mice used for long-term
follow-up obtained a fractionated scheme with adjusted indi-
vidual doses of 2 Gy from days 6 to 10 (HT-1080) or 3 Gy on days
13, 14, 16, 17, and 20 (MV3) after tumor implantation, amounting
to cumulative 10 Gy (HT-1080) or 15 Gy (MV3; Fig. 7 A). This
middose scheme was established by dose escalation and long-
term monitoring to yield relapse frequencies of 60–80%, cor-
responding to ~30% cure rate, for detecting the long-term effects
of radiosensitization by integrin-targeted combination therapy
(Fig. S5 G).
Immunohistological stainings
For the visualization of cell–cell junctions via ALCAM staining,
untreated tumor-bearing mice carrying the skin window were
sacrificed on day 5 (HT-1080) or day 8 (MV3) after tumor im-
plantation. Tumor-containing dorsal skin samples were cry-
opreserved as described above, with marked orientation of
invasion strands and invasion status documented by intravital
epifluorescencemicroscopy. Frozen tissue samples were cut into
50-µm-thick cryosections (HM500OM Cryostat Microtome,
Microm) that were immediately incubated in neutral buffered
formalin (4%, formulation according to Lillie; ∼18 h, room
temperature [RT]) and stored in phosphate buffer (0.1M, pH 7.4,
4°C). For staining, free aldehyde groups and unspecific epitopes
were blocked using 0.15% glycine in Tris-buffered saline (TBS;
30 min, RT), followed by incubation with TBS supplemented
with 1% BSA (Sigma-Aldrich) and 15% normal goat serum (NGS;
30–60 min, RT; Gibco Life Technologies). After washing (TBS),
endogenous mouse IgG in the tissue was blocked with unlabeled
anti-mouse IgG Fab9 fragments (115-007-003,∼18 h, 4°C; Jackson
ImmunoResearch) followed by washing (TBS). Mouse anti-
ALCAM mAb (AZN-L50; IgG2A; kindly provided by Joost te
Riet, Department of Tumor Immunology, Radboudumc, Nijme-
gen, Netherlands; Nelissen et al., 2000) was biotinylated using
biotin-SP (long-spacer) conjugated anti-mouse IgG Fab fragment
(115-067-003, 1:2, 20 min, RT; Jackson ImmunoResearch), fol-
lowed by incubation in mouse serum (10 µl/1 µg Fab9 biotin,
10 min, RT; Biowest). Anti-ALCAM/biotin-Fab9 complexes were
diluted (1:15) in TBS/BSA (1%) and added to the tissue slices for
incubation (∼18 h, 4°C). After washing (TBS), tissue slices were
overlaid with streptavidin-coupled Alexa Fluor 647 (016-600-
084, 2 µg/ml; Jackson ImmunoResearch) and DAPI (1 µg/ml;
Roche), in TBS/BSA (1%, 20 min, RT), washed (TBS), and
mounted in Fluoromount G (Southern Biotech) on object slides
for confocal microscopy.
For analysis of DDR markers, nonirradiated or irradiated
tumors (day 4 or 5) grown in the imaging windowwere obtained
before or 30–60 min and 23–24 h after IR. Tumor-containing
skin samples were cryopreserved with marked invasion status
as described above. Frozen tissue samples were cut into 10-µm
cryosections (HM500 Cryostat Microtome, Microm), mounted
on Superfrost-plus object slides and screened to determine tu-
mor subregion as core or invasion zone. After drying for ∼18 h,
tissue slices were stored (−80°C) and, before staining, fixed (2%
paraformaldehyde diluted in PHEM buffer [Pipes, Hepes, EGTA,
and MgCl2], 15 min, RT), rinsed with PBS, and incubated in PBS
containing 0.1% Triton X-100 (Sigma-Aldrich) for per-
meabilization (20 min, RT). To minimize background, samples
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were incubated in PBS supplemented with 5% NGS and 0.1%
coldwater fish skin gelatin (CWFG; 30 min, RT; Sigma-Aldrich),
followed by staining with the following primary antibodies:
rabbit anti-γH2AX (pSer139, NB-100-384, 1:10,000; stock con-
centration 1 mg/ml; Novus Biologicals), rabbit anti-
phosphoChk2 (pThr68, ab85743, 1:1,000; stock concentration
0.6 mg/ml; Abcam), or rabbit anti-phospho(Ser/Thr)-ATM/
ATR-substrates (4F7, 2909, 1:1,000; Cell Signaling), all diluted in
PBS supplemented with 2% NGS and 0.1% CWFG. Tissue slices
were incubated with primary antibody solution (1 h at RT fol-
lowed by ∼18 h at 4°C); washed (PBS); incubated with goat anti-
rabbit IgG (heavy and light chain [H+L]) Alexa Fluor 647
(A-21245, 4 µg/ml; Invitrogen) and DAPI (1 µg/ml), both diluted
in PBS/NGS (2%)/CWFG (0.1%); washed; and mounted in Fluo-
romount G. For reliable intratumor comparison of subregions,
all slices per tumor sample and staining were processed and
recorded in parallel.
Hypoxia and phospho-p44/42-MAPK signals were detected
in tumors 7 d after implantation from window-bearing mice. As
a hypoxia probe, pimonidazole (Hypoxyprobe-1 Kit, Hypoxyp-
robe) was applied i.p. (60 mg/kg body weight), and tissue was
harvested 60 min thereafter. Tumor-containing samples were
cryopreserved with marked invasion status and processed as 10-
µm-thick cryosections. Fixation, staining, and mounting were
performed as described for immunohistological analysis of DDR
markers using primary rat anti-CD31 (clone MEC13.3, 1:100,
blood vessel staining; BD Biosciences), mouse anti-pimonidazole
adducts (Hypoxyprobe-1 Kit, staining hypoxic cells), and rabbit
anti-phospho-p44/42-MAPK antibody (Thr202/Tyr204, 9101, 1:
50, phospho-Erk1/2 signal; Cell Signaling) and secondary goat
anti-rat, anti-rabbit, or anti-mouse IgG (H+L) Alexa Fluor 488 or
647 (Invitrogen) antibodies.
3D in vitro collagen cultures of irradiated MV3 tumoroids
were prepared and fixed as described (Veelken et al., 2017).
Immunostaining was performed using rabbit anti-cleaved
caspase-3 antibody (clone 5A1E, 9664, 1:200; Cell Signaling
Technology) and goat anti-rabbit Alexa Fluor 568 (1:400; In-
vitrogen; Veelken et al., 2017).
Image acquisition and analysis
Tissue samples stained for ALCAM and DDR markers were an-
alyzed by confocal microscopy (Olympus FV1000) as 3D stacks.
ALCAM stainings were recorded using either a 20×/0.50 NA
water or 60×/1.35 NA oil immersion objective with 3- or 1-µm
step size, respectively. Stainings of DDR markers were scanned
with a 40×/0.80 NA water immersion objective and 3-µm step
size to represent the whole 10-µm tissue slice using identical
instrument settings for each tumor sample and staining. Hy-
poxia and phosphoErk staining were scanned as z-stacks (2-µm
step depth) on an LSM 510 META confocal microscope (Zeiss).
Using Fiji/ImageJ software (v1.48; Schindelin et al., 2012),
DDR staining in tumor subregions was analyzed from average-
intensity projections of ∼10-µm 3D stacks, followed by image
segmentation using the H2B-EGFP signal to identify and mark
the edges of tumor nuclei (Fig. S3 C). Compared with maximum-
intensity projections, the average-intensity projection resulted
in cleaner image segmentation with fewer regions of interest
≤1 µm2 incurred from irrelevant particles and background noise
signal (data not shown). The mean gray value representing an
individual DDR signal was quantified for large nuclear segments
(≥38 µm2) representing intact, nonapoptotic nuclei, and the
values were corrected for the background signal measured in
nonnuclear regions (Fig. S3, C and D). Because image acquisition
was optimized to identify intratumor heterogeneity, direct
comparison of data points from different time points was
obsolete.
Immunohistochemistry
Human tissue was fixed in 4% PBS-buffered formalin, routinely
processed, and paraffin embedded. Mouse dorsal skin was cry-
opreserved as described above. 2–4-µm-thick sections of human
tissue and 10-µm-thick sections of mouse tissue were stained
with H&E and subsequently immunohistochemically stained by
HRP reaction using mouse monoclonal anti-human α-smooth
muscle actin (clone 1A4, DAKO, 1:500) or in-house-generated
rabbit polyclonal anti-GFP (Department of Cell Biology, Rad-
boudumc, Nijmegen, Netherlands; Cuppen, 1999) after antigen
retrieval. Slide scanning was performed on a Leica DM6000B
microscope (2.5× to 40× objectives, NA 0.07, 0.15, 0.3, 0.5, 0.75).
Protein gel electrophoresis and Western blot
β1 integrin knockdown efficiency in HT-1080 cells was detected
by protein gel electrophoresis and Western blot analysis using
whole-cell lysates. β1 integrin was detected with mouse anti-
β1 integrin (clone 18/CD29, 0.25 µg/ml; BD Biosciences) and
α-tubulin, as loading control with mouse anti-α-tubulin (clone
DM1A; 1 µg/ml; Millipore). All protein samples were separated
under reducing conditions on 8% SDS-PAGE and transferred
onto a nitrocellulose membrane, blocked with 2% milk–PBS-
Tween (1 h, RT), incubated with primary antibody (∼18 h,
4°C), washed with PBS-Tween, and incubated with HRP-
conjugated anti-mouse antibody (1 h, RT; Jackson Immuno-
Research). Protein bands were detected using luminol/H2O2. To
detect multiple proteins on the same membrane, membranes
were stripped using Restore Western Blot Stripping buffer
(Thermo Fisher Scientific), blocked again, and labeled with
subsequent primary and secondary antibody.
Flow cytometry
The surface expression of adhesion molecules on HT-1080 wild-
type, vector control (p-puro or p-puro/p-neo), and stable
knockdown (β1RNAi or β1/β3RNAi) cells and wild-type MV3
melanoma cells were obtained using cells from 3D matrix con-
ditions after 24-h culture in 3D collagen lattices. Suspended cells
were obtained by digestion with collagenase I (1,000 U/ml,
30 min, 37°C; Sigma-Aldrich), pelleted, and stained for 30 min
on ice with the following monoclonal antibodies or isotypic
control antibody: mouse anti-α1 integrin (clone TS2/7, 10 µg/ml;
Abcam); mouse anti-α2 (CD49b, clone AK-7, 5 µg/ml), mouse
anti-α3 integrin (CD49c, clone C3II.1, 0.25 µg/ml; both BD Bio-
sciences); mouse anti-α5 integrin (clone SAM-1, 400 µg/ml;
Millipore); rat anti-α6 integrin (CD49f, clone GoH3, 2.5 µg/ml;
BD Biosciences); mouse anti-αV (CD51, clone AMF7, 50 mg/ml;
Beckman Coulter); mouse anti-β1 (CD29, clone 4B4, 10 µg/ml),
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mouse anti-β2 (CD18, clone 7E4, 10 µg/ml), mouse anti-β3 in-
tegrin (CD61, clone SZ21, 15 µg/ml; all Beckman Coulter); rat
anti-β4 (CD104, clone 439-9B, 0.625 µg/ml; BD Biosciences);
mouse anti-β5 integrin (clone EM09902, 2 µg/ml; Absolute
Antibody); mouse anti-β6 (clone 437211, 0.5 µg/ml; R&D Sys-
tems); rat anti-β7 integrin (clone FIB504, 0.3125 µg/ml; BD Bi-
osciences); mouse anti-β8 integrin (clone 416922, 10 µg/ml; R&D
Systems); and isotypic mouse IgG1κ (cloneMOPC-21) and IgG2bκ
(clone 27-35), rat IgG2aκ (clone R35-95), and IgG2bκ (clone A95-
1; all BD Biosciences). Integrin α4 was not included in the panel,
as its expression has been shown to be restricted to leukocytes.
When primary antibody was unconjugated, secondary mouse
IgG (H+L) antibodies conjugated to Alexa Fluor 488 (20 µg/ml;
Invitrogen) were used for detection. Viability of cells was ob-
tained using propidium iodide (1 µg/ml) exclusion.
For measurement of residual β1 integrin epitopes after
shRNA-mediated downregulation, cells were preincubated (45
min, 4°C) with unconjugated anti-β1 mAb 4B4 or isotypic IgG1κ
(10 µg/ml), washed (PBS, 4°C), and incubated with FITC-
conjugated mAb4B4 (10 µg/ml, 45 min, 4°C) to detect available
β1 integrin epitopes.
Statistical analysis
For comparative analysis of DDR markers in tumor subregions,
data were log transformed, and a longitudinal analysis in the
form of a mixed-model ANOVA was performed using the lmer
function of the R package lme4 (Bates et al., 2015). Per DDR
marker and time point (before/after IR), differences between
the variables “tumor sample” and “subregion” (i.e., core versus
invasion zone) were analyzed. Due to the high number of data
points and high intertumor variability, each comparison be-
tween tumor subregions resulted in statistically significant
differences, even when independent replicates of the same
condition were compared based on quantitatively minor sam-
ple-to-sample variation with typically inconsistent trends (Fig.
S3 G, left panel). To separate biologically relevant effects from
background variability, comparisons showing inconsistent data
trends were considered nonsignificant, whereas analyses with
consistent trends (i.e., similar slope and direction of mean of
log values between tumor subregions; Fig. S3 G, right panel)
were considered biologically significant, with P values dis-
played. Survival of tumor-bearing mice during long-term
follow-up was analyzed using the Mantel–Cox log-rank test.
For all other statistical analyses, Student’s t test was used
for paired samples with Gaussian distribution. For indepen-
dent samples, irrespective of distribution, the two-tailed
Mann–Whitney U test was used. For all multiple analyses,
Bonferroni correction was performed. Unless mentioned oth-
erwise, GraphPad Prism 5 or 6 software was used for statistical
analysis.
Online supplemental material
Fig. S1 shows kinetics and organization of collective invasion in
mouse dermis and comparison to human samples. Fig. S2 shows
workflow and quantitative analysis of the radiation response of
sarcoma and melanoma tumor subregions monitored by intra-
vital microscopy. Fig. S3 shows tumor subregion analysis of the
DDR by serial sectioning and image analysis. Fig. S4 shows
integrin expression profiles in HT-1080 and MV3 cells and
RNAi-based integrin targeting in HT-1080 cells. Fig. S5 shows
radiosensitization of sarcoma and melanoma tumors by
antibody-based integrin interference and procedures and out-
come of long-term therapy response. Table S1 shows survival
rates and tumor outcome for long-term follow up experiments
on integrin-targeted and IR therapy in HT-1080 sarcoma xeno-
grafts. Table S2 shows survival rates and tumor outcome for
long-term follow up experiments on integrin-targeted and IR
therapy in MV3 melanoma xenografts. Video 1 shows collective
invasion strands of a HT-1080 sarcoma xenograft. Video 2 shows
collective invasion strands of a MV3 melanoma xenograft. Video
3 shows differential radiation response in tumor core and col-
lective invasion niche in HT-1080 sarcoma xenografts detected
by intravital microscopy.
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